Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Pharvaris BV (PHVS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: PHVS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $34.08
Year Target Price $34.08
| 6 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 1 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 19.07% | Avg. Invested days 39 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 926.38M USD | Price to earnings Ratio - | 1Y Target Price 34.33 |
Price to earnings Ratio - | 1Y Target Price 34.33 | ||
Volume (30-day avg) - | Beta -2.85 | 52 Weeks Range 11.51 - 25.50 | Updated Date 06/29/2025 |
52 Weeks Range 11.51 - 25.50 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.28 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -31.88% | Return on Equity (TTM) -52.2% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 649118209 | Price to Sales(TTM) - |
Enterprise Value 649118209 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.38 | Shares Outstanding 54493100 | Shares Floating 21230528 |
Shares Outstanding 54493100 | Shares Floating 21230528 | ||
Percent Insiders 6.25 | Percent Institutions 89.49 |
Analyst Ratings
Rating 4.44 | Target Price 34.08 | Buy 2 | Strong Buy 6 |
Buy 2 | Strong Buy 6 | ||
Hold - | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Pharvaris BV
Company Overview
History and Background
Pharvaris BV is a clinical-stage biopharmaceutical company focused on developing novel therapies for rare diseases, particularly hereditary angioedema (HAE). Founded in 2015, it has progressed rapidly through clinical trials, aiming to address significant unmet needs in HAE treatment.
Core Business Areas
- Hereditary Angioedema (HAE) Therapeutics: Pharvaris focuses on developing oral bradykinin B2 receptor antagonists for the treatment and prevention of HAE attacks.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives and scientific advisors. The company has a streamlined organizational structure focused on research, development, and commercialization of its HAE therapies.
Top Products and Market Share
Key Offerings
- PHA121 (Deurocalcitide): PHA121 is an investigational oral B2 receptor antagonist being developed for acute HAE attacks. Currently in Phase 3 clinical trials. There is no marketed market share data at the moment. Competitors include Takeda (TAK), CSL Behring, and BioCryst Pharmaceuticals (BCRX).
- PHA121 (Deurocalcitide): PHA121 is also being developed for prophylactic treatment to prevent HAE attacks. Currently in Phase 2 clinical trials. There is no marketed market share data at the moment. Competitors include Takeda (TAK), CSL Behring, and BioCryst Pharmaceuticals (BCRX).
Market Dynamics
Industry Overview
The market for HAE therapies is growing, driven by increased awareness, improved diagnosis, and the development of novel treatments. The market is competitive, with several established players.
Positioning
Pharvaris aims to differentiate itself through its oral B2 receptor antagonist, offering a convenient alternative to existing injectable therapies.
Total Addressable Market (TAM)
The estimated TAM for HAE treatments is several billion USD. Pharvaris is positioned to capture a significant share with its oral therapies, assuming successful clinical trials and regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel oral B2 receptor antagonist
- Strong intellectual property position
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Reliance on successful clinical trials
- Limited commercialization experience
- Potential competition from established players
- Pipeline limited to HAE
Opportunities
- Expansion into other indications
- Strategic partnerships
- Acquisition by a larger pharmaceutical company
- Increasing HAE diagnosis rates
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from biosimilars
- Pricing pressures
Competitors and Market Share
Key Competitors
- TAK
- BCRX
Competitive Landscape
Pharvaris faces competition from established pharmaceutical companies with existing HAE therapies. Its oral formulation could provide a competitive advantage.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily related to the advancement of its clinical programs and its ability to secure financing.
Future Projections: Future growth is dependent on the successful development and commercialization of its HAE therapies. Analyst estimates vary widely depending on the perceived likelihood of success.
Recent Initiatives: Recent initiatives include the ongoing Phase 3 clinical trial for acute HAE and the Phase 2 trial for prophylactic treatment.
Summary
Pharvaris is a clinical-stage biopharmaceutical company with a focus on HAE. Its strength lies in its novel oral therapy and experienced team. Key risks include clinical trial outcomes and competition. Successful development and commercialization would make it a strong player in the HAE market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data are estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pharvaris BV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-02-05 | Co-Founder, CEO & Executive Director Mr. Berndt Axel Edvard Modig CPA, M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 119 | Website https://pharvaris.com |
Full time employees 119 | Website https://pharvaris.com | ||
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.